Northwire Canada EditionFriday, July 10, 2026
Northwire
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%

← Back to our analysis

Original News Release Routine +

Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26

Dallas, Texas--(Newsfile Corp. - June 26, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon has moved from commissioning and into early utilization, with growing customer volume setting up better fixed-cost absorption at Galesburg. The Company completed commissioning and launched commercial production across Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein in FY26. Revenue increased sequentially to $0.83M in 4Q26 from $0.74M in 3Q26, and management indicated current-quarter sales were tracking toward ~50% sequential growth based on April/May activity. Burcon also set a new production record, with daily output roughly 60% above January - March levels. As volume builds, the margin opportunity should come from better utilization, steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Burcon is moving into utilization ramp mode, with 4Q26 revenue of $0.83M and current-quarter sales tracking ~50% higher sequentially. Customer traction is broadening, with 30+ purchasing customers and 200+ active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9M completed, $3.0M undrawn, and management targeting $10M of CY26 sales. Click image above to view full announcement. About Stonegate Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 [email protected] Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303144
View at source ↗